Design Therapeutics (DSGN) Cash & Current Investments (2020 - 2026)

Design Therapeutics (DSGN) has 7 years of Cash & Current Investments data on file, last reported at $222.8 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Current Investments fell 2.98% year-over-year to $222.8 million; the trailing twelve-month figure through Mar 2026 stood at $222.8 million (down 2.98% YoY), and the FY2025 full-year result was $219.8 million, down 10.44% from the prior year.
• Cash & Current Investments grew to $222.8 million in Q1 2026, from $219.8 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $371.2 million in Q1 2022 to a low of $206.0 million in Q3 2025.
• A 5-year average of $277.8 million and a median of $270.7 million in 2024 frame the typical range for Cash & Current Investments.
• Across the five-year window, Cash & Current Investments retreated 18.93% in 2025 and retreated 2.98% in 2026, its largest moves.
• Tracing DSGN's Cash & Current Investments over 5 years: stood at $330.4 million in 2022, then decreased by 14.71% to $281.8 million in 2023, then slipped by 12.89% to $245.5 million in 2024, then dropped by 10.44% to $219.8 million in 2025, then gained by 1.35% to $222.8 million in 2026.
• Business Quant data shows DSGN's Cash & Current Investments at $222.8 million in Q1 2026, $219.8 million in Q4 2025, and $206.0 million in Q3 2025.